Alzheimer's disease in a dish: Promises and challenges of human stem cell models

Human Molecular Genetics

Volumn 21, Issue R1, 2012, Pages

  Young, Jessica E ^a,b   Goldstein, Lawrence S B ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SANFORD CONSORTIUM FOR REGENERATIVE MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; BETA SECRETASE INHIBITOR; DONEPEZIL; GAMMA SECRETASE INHIBITOR; MEMANTINE; NONSTEROID ANTIINFLAMMATORY AGENT; PRESENILIN 1; PRESENILIN 2; SULINDAC SULFIDE; TAU PROTEIN;

ALZHEIMER DISEASE; ARTICLE; DISEASE COURSE; DOWN SYNDROME; DRUG SCREENING; HUMAN; NERVE CELL; NEUROFIBRILLARY TANGLE; PHENOTYPE; POINT MUTATION; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; STEM CELL;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN PRECURSOR; CELL DIFFERENTIATION; DOWN SYNDROME; HUMANS; INDUCED PLURIPOTENT STEM CELLS; NEURONS; PHENOTYPE; STEM CELL RESEARCH; TAU PROTEINS;

EID: 84867131908     PISSN: 09646906     EISSN: 14602083     Source Type: Journal    
DOI: 10.1093/hmg/dds319     Document Type: Article

References (76)

1. Barnes, D.E. and Yaffe, K. (2011) The projected effect of risk factor reduction on Alzheimer's disease prevalence. Lancet Neurol., 10, 819-828.
2. Holtzman, D.M., Morris, J.C. and Goate, A.M. (2011) Alzheimer's disease: the challenge of the second century. Sci. Transl. Med., 3, 77sr71.
3. Lunn, J.S., Sakowski, S.A., Hur, J. and Feldman, E.L. (2011) Stem cell technology for neurodegenerative diseases. Ann. Neurol, 70, 353-361.
4. Duff, K. and Suleman, F. (2004) Transgenic mouse models of Alzheimer's disease: how useful have they been for therapeutic development? Brief Funct. Genomic. Proteomic., 3, 47-59.
5. Takahashi, K., Tanabe, K., Ohnuki, M., Narita, M., Ichisaka, T., Tomoda, K. and Yamanaka, S. (2007) Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell, 131, 861-872.
6. Hussein, S.M., Batada, N.N., Vuoristo, S., Ching, R.W., Autio, R., Narva, E., Ng, S., Sourour, M., Hamalainen, R., Olsson, C. et al. (2011) Copy number variation and selection during reprogramming to pluripotency. Nature, 471, 58-62.
7. Gore, A., Li, Z., Fung, H.L., Young, J.E., Agarwal, S., Antosiewicz-Bourget, J., Canto, I., Giorgetti, A., Israel, M.A., Kiskinis, E. et al. (2011) Somatic coding mutations in human induced pluripotent stem cells. Nature, 471, 63-67.
8. Lister, R., Pelizzola, M., Kida, Y.S., Hawkins, R.D., Nery, J.R., Hon, G., Antosiewicz-Bourget, J., O'Malley, R., Castanon, R., Klugman, S. et al. (2011) Hotspots of aberrant epigenomic reprogramming in human induced pluripotent stem cells. Nature, 471, 68-73.
9. Lee, V.M., Brunden, K.R., Hutton, M. and Trojanowski, J.Q. (2011) Developing therapeutic approaches to tau, selected kinases, and related neuronal protein targets. Cold Spring Harb. Perspect. Med., 1, a006437.
10. Goldstein, L.S. (2012) Axonal transport and neurodegenerative disease: can we see the elephant? Prog. Neurobiol. http://dx.doi.org/10.1016/j. pneurobio.2012.03.006.
11. Gunawardena, S. and Goldstein, L.S. (2001) Disruption of axonal transport and neuronal viability by amyloid precursor protein mutations in Drosophila. Neuron, 32, 389-401.
12. Lazarov, O. and Demars, M.P. (2012) All in the family: how the APPs regulate neurogenesis. Front Neurosci., 6, 81.
13. Brunholz, S., Sisodia, S., Lorenzo, A., Deyts, C., Kins, S. and Morfini, G. (2012) Axonal transport of APP and the spatial regulation of APP cleavage and function in neuronal cells. Exp. Brain Res., 217, 353-364.
14. Nixon, R.A. and Yang, D.S. (2011) Autophagy failure in Alzheimer's disease-locating the primary defect. Neurobiol. Dis., 43, 38-45.
15. Selkoe, D.J. (2011) Alzheimer's disease. Cold Spring Harb. Perspect. Biol., 3.
16. Hardy, J.A. and Higgins, G.A. (1992) Alzheimer's disease: the amyloid cascade hypothesis. Science, 256, 184-185.
17. Buerger, K., Ewers, M., Pirttila, T., Zinkowski, R., Alafuzoff, I., Teipel, S.J., DeBernardis, J., Kerkman, D., McCulloch, C., Soininen, H. et al. (2006) CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer's disease. Brain, 129, 3035-3041.
18. Buerger, K., Teipel, S.J., Zinkowski, R., Blennow, K., Arai, H., Engel, R., Hofmann-Kiefer, K., McCulloch, C., Ptok, U., Heun, R. et al. (2002) CSF tau protein phosphorylated at threonine 231 correlates with cognitive decline in MCI subjects. Neurology, 59, 627-629.
19. Avramopoulos, D. (2009) Genetics of Alzheimer's disease: recent advances. Genome Med., 1, 34.
20. Gatz, M., Reynolds, C.A., Fratiglioni, L., Johansson, B., Mortimer, J.A., Berg, S., Fiske, A. and Pedersen, N.L. (2006) Role of genes and environments for explaining Alzheimer disease. Arch. Gen. Psychiatry, 63, 168-174.
21. Rogaeva, E., Meng, Y., Lee, J.H., Gu, Y., Kawarai, T., Zou, F., Katayama, T., Baldwin, C.T., Cheng, R., Hasegawa, H. et al. (2007) The neuronal sortilin-related receptor SORL1 is genetically associated with Alzheimer disease. Nat. Genet., 39, 168-177.
22. Lambert, J.C., Heath, S., Even, G., Campion, D., Sleegers, K., Hiltunen, M., Combarros, O., Zelenika, D., Bullido, M.J., Tavernier, B. et al. (2009) Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. Nat. Genet., 41, 1094-1099.
23. Harold, D., Abraham, R., Hollingworth, P., Sims, R., Gerrish, A., Hamshere, M.L., Pahwa, J.S., Moskvina, V., Dowzell, K., Williams, A. et al. (2009) Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat. Genet., 41, 1088-1093.
24. Tayeb, H.O., Yang, H.D., Price, B.H. and Tarazi, F.I. (2012) Pharmacotherapies for Alzheimer's disease: beyond cholinesterase inhibitors. Pharmacol. Ther., 134, 8-25.
25. Reitz, C. (2012) Alzheimer's disease and the amyloid cascade hypothesis: a critical review. Int. J. Alzheimers Dis., 2012, 369808.
26. Park, I.H., Arora, N., Huo, H., Maherali, N., Ahfeldt, T., Shimamura, A., Lensch, M.W., Cowan, C., Hochedlinger, K. and Daley, G.Q. (2008) Disease-specific induced pluripotent stem cells. Cell, 134, 877-886.
27. Soldner, F., Hockemeyer, D., Beard, C., Gao, Q., Bell, G.W., Cook, E.G., Hargus, G., Blak, A., Cooper, O., Mitalipova, M. et al. (2009) Parkinson's disease patient-derived induced pluripotent stem cells free of viral reprogramming factors. Cell, 136, 964-977.
28. Nguyen, H.N., Byers, B., Cord, B., Shcheglovitov, A., Byrne, J., Gujar, P., Kee, K., Schule, B., Dolmetsch, R.E., Langston, W. et al. (2011) LRRK2 mutant iPSC-derived DA neurons demonstrate increased susceptibility to oxidative stress. Cell Stem Cell, 8, 267-280.
29. Seibler, P., Graziotto, J., Jeong, H., Simunovic, F., Klein, C. and Krainc, D. (2011) Mitochondrial Parkin recruitment is impaired in neurons derived from mutant PINK1 induced pluripotent stem cells. J. Neurosci., 31, 5970-5976.
30. Dimos, J.T., Rodolfa, K.T., Niakan, K.K., Weisenthal, L.M., Mitsumoto, H., Chung, W., Croft, G.F., Saphier, G., Leibel, R., Goland, R. et al. (2008) Induced pluripotent stem cells generated from patients with ALS can be differentiated into motor neurons. Science, 321, 1218-1221.
31. Mitne-Neto, M., Machado-Costa, M., Marchetto, M.C., Bengtson, M.H., Joazeiro, C.A., Tsuda, H., Bellen, H.J., Silva, H.C., Oliveira, A.S., Lazar, M. et al. (2011) Downregulation of VAPB expression in motor neurons derived from induced pluripotent stem cells of ALS8 patients. Hum. Mol. Genet., 20, 3642-3652.
32. Ebert, A.D., Yu, J., Rose, F.F. Jr., Mattis, V.B., Lorson, C.L., Thomson, J.A. and Svendsen, C.N. (2009) Induced pluripotent stem cells from a spinal muscular atrophy patient. Nature, 457, 277-280.
33. Lee, G., Papapetrou, E.P., Kim, H., Chambers, S.M., Tomishima, M.J., Fasano, C.A., Ganat, Y.M., Menon, J., Shimizu, F., Viale, A. et al. (2009) Modelling pathogenesis and treatment of familial dysautonomia using patient-specific iPSCs. Nature, 461, 402-406.
34. Marchetto, M.C., Brennand, K.J., Boyer, L.F. and Gage, F.H. (2011) Induced pluripotent stem cells (iPSCs) and neurological disease modeling: progress and promises. Hum. Mol. Genet., 20, R109-R115.
35. Marchetto, M.C., Carromeu, C., Acab, A., Yu, D., Yeo, G.W., Mu, Y., Chen, G., Gage, F.H. and Muotri, A.R. (2010) A model for neural development and treatment of Rett syndrome using human induced pluripotent stem cells. Cell, 143, 527-539.
36. Brennand, K.J., Simone, A., Jou, J., Gelboin-Burkhart, C., Tran, N., Sangar, S., Li, Y., Mu, Y., Chen, G., Yu, D. et al. (2011) Modelling schizophrenia using human induced pluripotent stem cells. Nature, 473, 221-225.
37. Yagi, T., Ito, D., Okada, Y., Akamatsu, W., Nihei, Y., Yoshizaki, T., Yamanaka, S., Okano, H. and Suzuki, N. (2011) Modeling familial Alzheimer's disease with induced pluripotent stem cells. Hum. Mol. Genet., 20, 4530-4539.
38. Qiang, L., Fujita, R., Yamashita, T., Angulo, S., Rhinn, H., Rhee, D., Doege, C., Chau, L., Aubry, L., Vanti, W.B. et al. (2011) Directed conversion of Alzheimer's disease patient skin fibroblasts into functional neurons. Cell, 146, 359-371.
39. Vierbuchen, T., Ostermeier, A., Pang, Z.P., Kokubu, Y., Sudhof, T.C. and Wernig, M. (2010) Direct conversion of fibroblasts to functional neurons by defined factors. Nature, 463, 1035-1041.
40. Koch, P., Tamboli, I.Y., Mertens, J., Wunderlich, P., Ladewig, J., Stuber, K., Esselmann, H., Wiltfang, J., Brustle, O. and Walter, J. (2012) Presenilin-1 L166P mutant human pluripotent stem cell-derived neurons exhibit partial loss of gamma-secretase activity in endogenous amyloid-beta generation. Am. J. Pathol., 180, 2404-2416.
41. Koch, P., Opitz, T., Steinbeck, J.A., Ladewig, J. and Brustle, O. (2009) A rosette-type, self-renewing human ES cell-derived neural stem cell with potential for in vitro instruction and synaptic integration. Proc. Natl Acad. Sci. USA, 106, 3225-3230.
42. Moehlmann, T., Winkler, E., Xia, X., Edbauer, D., Murrell, J., Capell, A., Kaether, C., Zheng, H., Ghetti, B., Haass, C. et al. (2002) Presenilin-1 mutations of leucine 166 equally affect the generation of the Notch and APP intracellular domains independent of their effect on Abeta 42 production. Proc. Natl Acad. Sci. USA, 99, 8025-8030.
43. Rovelet-Lecrux, A., Hannequin, D., Raux, G., Le Meur, N., Laquerriere, A., Vital, A., Dumanchin, C., Feuillette, S., Brice, A., Vercelletto, M. et al. (2006) APP locus duplication causes autosomal dominant early-onset Alzheimer disease with cerebral amyloid angiopathy. Nat. Genet., 38, 24-26.
44. Lemere, C.A., Blusztajn, J.K., Yamaguchi, H., Wisniewski, T., Saido, T.C. and Selkoe, D.J. (1996) Sequence of deposition of heterogeneous amyloid beta-peptides and APO E in Down syndrome: implications for initial events in amyloid plaque formation. Neurobiol. Dis., 3, 16-32.
45. Nixon, R.A. (2007) Autophagy, amyloidogenesis and Alzheimer disease. J. Cell Sci., 120, 4081-4091.
46. Cataldo, A.M., Hamilton, D.J., Barnett, J.L., Paskevich, P.A. and Nixon, R.A. (1996) Abnormalities of the endosomal-lysosomal system in Alzheimer's disease: relationship to disease pathogenesis. Adv. Exp. Med. Biol., 389, 271-280.
47. Nixon, R.A., Wegiel, J., Kumar, A., Yu, W.H., Peterhoff, C., Cataldo, A. and Cuervo, A.M. (2005) Extensive involvement of autophagy in Alzheimer disease: an immuno-electron microscopy study. J. Neuropathol. Exp. Neurol., 64, 113-122.
48. Cataldo, A.M., Peterhoff, C.M., Schmidt, S.D., Terio, N.B., Duff, K., Beard, M., Mathews, P.M. and Nixon, R.A. (2004) Presenilin mutations in familial Alzheimer disease and transgenic mouse models accelerate neuronal lysosomal pathology. J. Neuropathol. Exp. Neurol., 63, 821-830.
49. Lee, J.H., Yu, W.H., Kumar, A., Lee, S., Mohan, P.S., Peterhoff, C.M., Wolfe, D.M., Martinez-Vicente, M., Massey, A.C., Sovak, G. et al. (2010) Lysosomal proteolysis and autophagy require presenilin 1 and are disrupted by Alzheimer-related PS1 mutations. Cell, 141, 1146-1158.
50. Israel, M.A., Yuan, S.H., Bardy, C., Reyna, S.M., Mu, Y., Herrera, C., Hefferan, M.P., Van Gorp, S., Nazor, K.L., Boscolo, F.S. et al. (2012) Probing sporadic and familial Alzheimer's disease using induced pluripotent stem cells. Nature, 482, 216-220.
51. Yuan, S.H., Martin, J., Elia, J., Flippin, J., Paramban, R.I., Hefferan, M.P., Vidal, J.G., Mu, Y., Killian, R.L., Israel, M.A. et al. (2011) Cell-surface marker signatures for the isolation of neural stem cells, glia and neurons derived from human pluripotent stem cells. PLoS One, 6, e17540.
52. Cho, J.H. and Johnson, G.V. (2004) Primed phosphorylation of tau at Thr231 by glycogen synthase kinase 3beta (GSK3beta) plays a critical role in regulating tau's ability to bind and stabilize microtubules. J. Neurochem., 88, 349-358.
53. Salehi, A., Delcroix, J.D., Belichenko, P.V., Zhan, K., Wu, C., Valletta, J.S., Takimoto-Kimura, R., Kleschevnikov, A.M., Sambamurti, K., Chung, P.P. et al. (2006) Increased App expression in a mouse model of Down's syndrome disrupts NGF transport and causes cholinergic neuron degeneration. Neuron, 51, 29-42.
54. Cataldo, A.M., Peterhoff, C.M., Troncoso, J.C., Gomez-Isla, T., Hyman, B.T. and Nixon, R.A. (2000) Endocytic pathway abnormalities precede amyloid beta deposition in sporadic Alzheimer's disease and Down syndrome: differential effects of APOE genotype and presenilin mutations. Am. J. Pathol., 157, 277-286.
55. Cataldo, A.M., Mathews, P.M., Boiteau, A.B., Hassinger, L.C., Peterhoff, C.M., Jiang, Y., Mullaney, K., Neve, R.L., Gruenberg, J. and Nixon, R.A. (2008) Down syndrome fibroblast model of Alzheimer-related endosome pathology: accelerated endocytosis promotes late endocytic defects. Am. J. Pathol., 173, 370-384.
56. Stokin, G.B., Almenar-Queralt, A., Gunawardena, S., Rodrigues, E.M., Falzone, T., Kim, J., Lillo, C., Mount, S.L., Roberts, E.A., McGowan, E. et al. (2008) Amyloid precursor protein-induced axonopathies are independent of amyloid-beta peptides. Hum. Mol. Genet., 17, 3474-3486.
57. Shi, Y., Kirwan, P., Smith, J., MacLean, G., Orkin, S.H. and Livesey, F.J. (2012) A human stem cell model of early Alzheimer's disease pathology in Down syndrome. Sci. Transl. Med., 4, 124ra129.
58. Shi, Y., Kirwan, P., Smith, J., Robinson, H.P. and Livesey, F.J. (2012) Human cerebral cortex development from pluripotent stem cells to functional excitatory synapses. Nat. Neurosci., 15, 477-486, S471.
59. Holtzman, D.M. (2011) CSF biomarkers for Alzheimer's disease: current utility and potential future use. Neurobiol. Aging, 32 (Suppl. 1), S4-S9.
60. Yahata, N., Asai, M., Kitaoka, S., Takahashi, K., Asaka, I., Hioki, H., Kaneko, T., Maruyama, K., Saido, T.C., Nakahata, T. et al. (2011) Anti-Abeta drug screening platform using human iPS cell-derived neurons for the treatment of Alzheimer's disease. PLoS One, 6, e25788.
61. Geling, A., Steiner, H., Willem, M., Bally-Cuif, L. and Haass, C. (2002) A gamma-secretase inhibitor blocks Notch signaling in vivo and causes a severe neurogenic phenotype in zebrafish. EMBO Rep., 3, 688-694.
62. Gasparini, L., Ongini, E. and Wenk, G. (2004) Non-steroidal anti-inflammatory drugs (NSAIDs) in Alzheimer's disease: old and new mechanisms of action. J. Neurochem., 91, 521-536.
63. Czirr, E., Leuchtenberger, S., Dorner-Ciossek, C., Schneider, A., Jucker, M., Koo, E.H., Pietrzik, C.U., Baumann, K. and Weggen, S. (2007) Insensitivity to Abeta42-lowering nonsteroidal anti-inflammatory drugs and gamma-secretase inhibitors is common among aggressive presenilin-1 mutations. J. Biol. Chem., 282, 24504-24513.
64. Talan, J. (2010) In a large clinical trial, gamma-secreatase inhibitor Tarenflurbil is found ineffective for mild Alzheimer disease. Neurology Today, 10, 16-17.
65. Cathomen, T. and Joung, J.K. (2008) Zinc-finger nucleases: the next generation emerges. Mol. Ther., 16, 1200-1207.
66. Mussolino, C. and Cathomen, T. (2012) TALE nucleases: tailored genome engineering made easy. Curr. Opin. Biotechnol., doi: 10.1016/ j.copbio.2012.01.013.
67. Soldner, F., Laganiere, J., Cheng, A.W., Hockemeyer, D., Gao, Q., Alagappan, R., Khurana, V., Golbe, L.I., Myers, R.H., Lindquist, S. et al. (2011) Generation of isogenic pluripotent stem cells differing exclusively at two early onset Parkinson point mutations. Cell, 146, 318-331.
68. Wolfe, M.S. (2007) When loss is gain: reduced presenilin proteolytic function leads to increased Abeta42/Abeta40. Talking Point on the role of presenilin mutations in Alzheimer disease. EMBO Rep., 8, 136-140.
69. Shen, J. and Kelleher, R.J. 3rd (2007) The presenilin hypothesis of Alzheimer's disease: evidence for a loss-of-function pathogenic mechanism. Proc. Natl Acad. Sci. USA, 104, 403-409.
70. Guerreiro, R.J. and Hardy, J. (2011) Alzheimer's disease genetics: lessons to improve disease modelling. Biochem. Soc. Trans., 39, 910-916.
71. Vance, J.E., Hayashi, H. and Karten, B. (2005) Cholesterol homeostasis in neurons and glial cells. Semin. Cell Dev. Biol., 16, 193-212.
72. Olgiati, P., Politis, A.M., Papadimitriou, G.N., De Ronchi, D. and Serretti, A. (2011) Genetics of late-onset Alzheimer's disease: update from the alzgene database and analysis of shared pathways. Int. J. Alzheimers Dis., 2011, 832379.
73. Pallesen, L.T. and Vaegter, C.B. (2012) Sortilin and SorLA regulate neuronal sorting of trophic and dementia-linked proteins. Mol. Neurobiol., 45, 379-387.
74. Harel, A., Wu, F., Mattson, M.P., Morris, C.M. and Yao, P.J. (2008) Evidence for CALM in directing VAMP2 trafficking. Traffic, 9, 417-429.
75. Masliah, E., Mallory, M., Alford, M., DeTeresa, R., Hansen, L.A., McKeel, D.W. Jr and Morris, J.C. (2001) Altered expression of synaptic proteins occurs early during progression of Alzheimer's disease. Neurology, 56, 127-129.
76. Miura, K., Okada, Y., Aoi, T., Okada, A., Takahashi, K., Okita, K., Nakagawa, M., Koyanagi, M., Tanabe, K., Ohnuki, M. et al. (2009) Variation in the safety of induced pluripotent stem cell lines. Nat. Biotechnol., 27, 743-745.